Members Only Report

COVID-19 Preparedness and Reporting in Oncology Clinical Trials: Evaluating Prospective Planning and Subsequent Toxicity Documentation -- research paper

This research examines whether cancer clinical trials were prepared to account for COVID-19 as an unexpected clinical disruption. Using data from Phase III RCTs, we analyze how COVID-19 was incorporated into trial protocols and how consistently COVID-related toxicities were later reported.
Like

Share this post

Choose a social network to share with, or copy the URL to share elsewhere

This is a representation of how your post may appear on social media. The actual post will vary between social networks

Please sign in

If you are a registered user on Laidlaw Scholars Network, please sign in